U.S. Markets closed

Alimera Sciences, Inc. (ALIM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.31-0.57 (-8.28%)
At close: 4:00PM EDT

Alimera Sciences, Inc.

6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees122

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles Daniel MyersNon-Exec. Chairman & Consultant802.5kN/A1954
Mr. Richard S. Eiswirth Jr.Pres, CEO & Director534.49kN/A1968
Mr. David R. HollandCo-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets392.25kN/A1964
Dr. Philip AshmanCOO & Sr. VP of Commercial Operations - Europe365.95kN/A1965
Mr. J. Philip JonesChief Financial OfficerN/AN/A1964
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Alimera Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.